REKO
Pharmaceutical company · 32 brands · 42 molecules
Ranked #30 of 112 companies in Blood Glucose Lowering Drugs, Excluding Insulin
Company overview
REKO is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 32 product registrations across 42 distinct molecules. Its portfolio is concentrated in Blood Glucose Lowering Drugs, Excluding Insulin and Antiinflammatory And Antirheumatic Products. It has no DRAP recall, shortage or safety notices on record.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Top molecules by brand count
Therapeutic classes
Regulatory record
No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Get the full profile for REKO
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included